Type 2 diabetes does not appear overnight. By the time fasting glucose crosses the diagnostic threshold, the body has often been struggling with the underlying problem for years: in the British Whitehall II study, people who later developed diabetes already showed lower insulin sensitivity and higher glucose up to 13 years before diagnosis. During that entire period, a standard annual check-up has probably reported that everything was fine.
This is one of the most consequential blind spots in preventive medicine. The lab test that could identify the problem early is cheap, widely available and almost never ordered. Here is what actually happens during that silent decade, and why the relevant marker deserves a place in a preventive blood panel.
What actually happens before diabetes
The pancreas produces insulin, a hormone that tells cells to take glucose out of the bloodstream. When the system works normally, a small amount of insulin is enough to keep blood glucose stable.
Over time — especially with weight gain, physical inactivity, poor sleep and a diet heavy in refined carbohydrates — cells become less responsive to insulin. This is called insulin resistance. The pancreas compensates by producing more insulin. A lot more. In the early stages, glucose looks completely normal on a lab test, because the extra insulin is keeping it in range.
This compensation can go on for years. Fasting glucose stays under 100. HbA1c stays under 5.7%. The doctor says everything looks fine. Meanwhile, insulin levels are quietly climbing, and the metabolic stress is doing real damage — to the arteries, the liver, the cardiovascular system and cognitive health.
Stage 1: Early insulin resistance
Cells start responding less to insulin. The pancreas makes more to compensate. Fasting glucose is normal. HbA1c is normal. Glucose tests cannot detect this; fasting insulin and HOMA-IR — or indirect signs such as the triglyceride-to-HDL ratio and waist circumference — can point to it.
Stage 2: Hyperinsulinemia
Insulin levels are now significantly elevated. Triglycerides may start to rise. Liver enzymes may begin to drift up (fatty liver). Glucose is still normal. A standard check-up still says everything is fine.
Stage 3: Prediabetes
Insulin sensitivity falls steeply and glucose begins to rise, most sharply in the last three years. Fasting glucose enters the 100–125 mg/dL range. HbA1c reaches 5.7–6.4%. This is the first stage most check-ups can detect — but the problem has been brewing for a decade.
Stage 4: Type 2 diabetes
Pancreatic beta cells begin to fail. Glucose crosses the diabetic threshold (≥126 mg/dL fasting, ≥6.5% HbA1c). By this point, substantial vascular and metabolic damage has often already occurred.
Why the standard tests miss it
The standard metabolic check — fasting glucose and HbA1c — can only see the problem once it has progressed to stage 3 or later. These tests measure the end result of the system failing, not the early warning that it is about to (see also HbA1c vs fasting glucose).
Fasting glucose / HbA1c
Measures what glucose is doing right now. Only abnormal once compensation has failed. Often detects problems only years after they started.
Fasting insulin / HOMA-IR
Measures how hard the pancreas is working to keep glucose normal. Picks up insulin resistance years before glucose becomes abnormal. The early warning system.
What HOMA-IR actually measures
HOMA-IR — the Homeostatic Model Assessment of Insulin Resistance — is a simple calculation that uses fasting glucose and fasting insulin together. It yields a number that estimates how resistant the cells are to insulin. There are no universal cut-offs: insulin assays are not standardised, and reference values differ between laboratories and populations. Commonly used approximate guide values are:
- HOMA-IR < 2.0: Good insulin sensitivity
- HOMA-IR 2.0–2.5: Early insulin resistance — worth watching
- HOMA-IR > 2.5: Insulin resistance present — time to act
The test requires two measurements — fasting glucose (which is usually measured anyway) and fasting insulin (which usually is not). Measuring insulin is an inexpensive laboratory test. And yet most standard panels do not include it.
Why early detection matters so much
Here is the part that may genuinely surprise you. The Diabetes Prevention Program — one of the most important trials in preventive medicine — showed that in people with prediabetes, intensive lifestyle intervention reduced progression to diabetes by 58% over about three years. Not 5%. Not 15%. Fifty-eight percent.
Lifestyle change was also clearly more effective than the drug metformin, which reduced the risk by 31% compared with placebo (Diabetes Prevention Program, NEJM 2002).
The intervention was not exotic. It consisted of weight loss of about 7%, 150 minutes of exercise per week and dietary changes. What made it work was that it happened early enough — while the system was still responsive.
By the time diabetes is diagnosed, beta cells have already been damaged. Reversal is still possible in some cases, but it is much harder. Every year earlier that insulin resistance is caught is a year the pancreas does not have to compensate, a year less cardiovascular damage, a year of intact metabolic reserve.
Why this is almost never caught early
Fasting insulin is not on most standard panels because guidelines are built around diagnostic thresholds, not early detection. The guidelines say "screen for diabetes" — and for that, fasting glucose is enough. But if the goal is to prevent diabetes, not just diagnose it, you need to look years earlier.
Beyond HOMA-IR: the full metabolic picture
Insulin resistance rarely travels alone. When HOMA-IR is elevated, it makes sense to look at several related markers to understand the full metabolic picture:
- Triglyceride-to-HDL ratio: a useful indirect marker of insulin resistance; in one study of overweight adults, a ratio of about 3 or more (in mg/dL; about 1.8 in mmol/L) identified insulin resistance with moderate accuracy
- Uric acid: often elevated in metabolic syndrome, independent cardiovascular risk factor
- ALT (liver enzyme): often drifts upward with fatty liver — an early consequence of insulin resistance
- hs-CRP: measures systemic inflammation, which accompanies metabolic dysfunction
- Waist circumference and visceral fat (via DEXA or BIA): the fat around the organs matters far more than the fat under the skin
Together, these markers paint a much more accurate picture than fasting glucose alone. They show not just whether there is a problem, but how severe it is and what the right intervention should be.
A reasonable approach
An evidence-based metabolic assessment includes fasting glucose, HbA1c, fasting insulin with HOMA-IR calculation, triglycerides, HDL, uric acid, ALT and hs-CRP. All are inexpensive, routine laboratory tests — the main obstacle is simply that someone has to ask for them.
If HOMA-IR is elevated, or if related markers suggest metabolic stress, sensible next steps include an abdominal ultrasound to assess liver fat, body composition measurement (for example DEXA) to quantify visceral fat, and an extended lipid panel including ApoB. Most importantly, the results should lead to a specific intervention plan with your physician — not a generic "eat better and exercise" conversation, but a plan based on what the data actually show.
If HOMA-IR and the related markers are normal, no further work-up for insulin resistance is needed. That is how evidence-based preventive medicine works: the test directs the next step, not the marketing.
References
- Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
- McLaughlin T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809.
- Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
- Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221.
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.